Pesticides exposure and genetic polymorphism of paraoxonase in the susceptibility of Parkinson's disease

Acta Neurologica Taiwanica

Volumn 14, Issue 2, 2005, Pages 55-60

  Fong, Chin Shih ^a   Cheng, Chun Wen ^b   Wu, Ruey Meei ^c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Parkinson's disease; Pesticide; PON1 polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; DRINKING WATER;

ADULT; AGED; AGRICULTURAL WORKER; ARTICLE; BRADYKINESIA; CASE CONTROL STUDY; CHEEK MUCOSA; CODON; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RIGIDITY; TREMOR; XENOBIOTIC METABOLISM;

AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; DISEASE SUSCEPTIBILITY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PESTICIDES; POLYMORPHISM, GENETIC;

EID: 21544473194     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Le Couteur DG, McLean AJ, Taylor MC, et al. Pesticides and Parkinson's disease. Biomed Pharmacother 1999;53: 122-30.
2. Le Couteur DG, McCann SJ. P450 enzymes and Parkinson's disease. Mov Disord 1998; 13:851-2.
3. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
4. Mackness B, Mackness MI, Arrol S, et al. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997; 122:265-8.
5. Akhmedova S, Anisimov S, Yakimovsky A, et al. Gin-Arg 191 polymorphism of paraoxonase and Parkinson's disease. Hum Hered 1999;49:178-80.
6. Taylor MC, Le Couteur DG, Mellick GD, et al. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J Neural Transm 2000;107:979-83.
7. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associataed with modified serum concentration of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99:62-6.
8. Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord 1990;5:66-70.
9. Akhmedova SN, Yakimovsky AK, Schwartz EI. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci 2001;184:179-82.
10. Wang J, Liu Z. No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson's disease in a Chinese population. Mov Disord 2000;15:1265-7.
11. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 1996;46:1275-84.
12. Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology 1989;39: 1314-8.
13. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
14. Costa LG, Li WF, Richter RJ, et al. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 1999;119-120:429-38.
15. Blatter-Garin MC, Abbott Ca, Messmer S, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay. population differences in protein concentrations. Biochem J 1994;304:549-54.